樹突細胞癌症疫苗市場規模、佔有率和成長分析：按產品類型、疫苗類型、癌症類型、應用、最終用戶和地區分類－2026-2033年產業預測

2024 年全球樹突狀細胞癌疫苗市場價值為 8.2 億美元，預計到 2025 年將成長至 9.266 億美元，到 2033 年將成長至 24.6331 億美元，在預測期（2026-2033 年）內複合年成長率為 13.0%。

全球樹突細胞癌症疫苗市場正經歷顯著成長，這主要得益於癌症發生率的上升以及免疫學技術的進步，使得標靶抗原呈現成為可能。該市場涵蓋自體和異體樹突狀細胞療法，旨在激活細胞毒性T細胞，即使在傳統治療方法無效的情況下也能提供有效的解決方案。隨著市場從概念驗證（PoC）研究過渡到臨床開發，湧現許多顯著的創新成果，凸顯了個人化細胞免疫療法的有效性。關鍵促進因素包括增強抗原發現的技術整合，以及可降低成本並提高一致性的自動化生產流程。此外，人工智慧（AI）的應用透過最佳化患者選擇、簡化操作流程和提高臨床試驗效率，正在加速臨床開發，最終為在服務不足的適應症領域開展更廣泛的應用和合作鋪平道路。

樹突狀細胞癌疫苗市場的全球促進因素

全球樹突細胞癌疫苗市場的主要促進因素之一是對個人化癌症治療日益成長的需求。隨著免疫療法的進步不斷改變癌症治療的模式，醫療專業人員和患者都認知到樹突狀細胞疫苗誘導針對個別腫瘤抗原的強效免疫反應的潛力。這種向個人化醫療的轉變不僅將提高治療效果，還能最大限度地減少傳統治療方法帶來的副作用。此外，患者和醫療專業人員對免疫療法益處的認知不斷提高，也進一步推動了腫瘤市場這一創新領域的成長。

全球樹突細胞癌疫苗市場的限制因素

全球樹突狀細胞癌疫苗市場的主要限制因素之一是疫苗生產的高成本和複雜性。樹突細胞疫苗需要複雜的加工和處理，通常涉及個人化治療方案和勞動密集型操作。這種複雜性導致生產成本增加，使得醫療機構難以以可負擔的價格提供這些治療方法。此外，對專用設施和訓練有素人員的需求進一步限制了這些疫苗的擴充性和普及，這可能會阻礙其在競爭激烈的癌症治療領域中廣泛應用。

樹突狀細胞癌疫苗的全球市場趨勢

全球樹突細胞癌疫苗市場正經歷著向適應性聯合治療的顯著轉變，凸顯了透過協同治療方法增強抗腫瘤反應的潛力。隨著創新研究人員認知到將樹突狀細胞疫苗與其他免疫療法策略結合的有效性，研究重點正轉向開發序貫和同步治療方法。這種協同方法旨在最大限度地激活T細胞，同時利用查核點抑制劑、細胞激素佐劑或標靶治療來對抗腫瘤介導的免疫逃脫。市場正朝著更加重視合理治療方法設計、靈活的臨床試驗方法以及與研究界建立牢固夥伴關係的方向發展，所有這些都旨在拓展治療選擇，並透過快速臨床檢驗驗證療效。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 價值鏈分析
• 案例研究
• 技術評估
• 客戶和採購標準分析
• 管道分析
• 疾病流行病學

全球樹突細胞癌疫苗市場規模：依產品類型分類

• Siple Ethel-T（Provenge）
• CreaVax
• 其他

全球樹突細胞癌疫苗市場規模：依疫苗類型分類

• 自體疫苗
• 同型疫苗

全球樹突細胞癌症疫苗市場規模：依癌症類型分類

• 攝護腺癌
• 黑色素瘤
• 膠質母細胞瘤
• 乳癌
• 其他固體癌

樹突細胞癌症疫苗的全球市場規模：按應用領域分類。

• 癌症治療的治療目的
• 輔助性治療
• 聯合免疫療法

樹突細胞癌症疫苗的全球市場規模：依最終用戶分類

• 醫院
• 癌症治療中心
• 研究機構
• 其他

全球樹突細胞癌疫苗市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Dendreon Pharmaceuticals LLC
• Argos Therapeutics Inc.
• Immunicum AB
• Northwest Biotherapeutics Inc.
• DCPrime BV
• Medigene AG
• DanDrit Biotech A/S
• Kiromic Biopharma Inc.
• AIVITA Biomedical Inc.
• ImmunoCellular Therapeutics Ltd.
• Batavia Biosciences
• Bellicum Pharmaceuticals Inc.
• Elios Therapeutics
• Activarti
• Creagene Inc.
• Sanpower Corporation
• Merck & Co., Inc.
• Shenzhen Geno-Immune Medical Institute
• Tella Inc.
• OncoTherapy Science Inc.

結論與建議

Global Dendritic Cell Cancer Vaccine Market size was valued at USD 820.0 Million in 2024 and is poised to grow from USD 926.6 Million in 2025 to USD 2463.31 Million by 2033, growing at a CAGR of 13.0% during the forecast period (2026-2033).

The global dendritic cell cancer vaccine market is experiencing significant growth fueled by the increasing prevalence of cancer and advancements in immunology, which enable targeted antigen presentation. This market encompasses both autologous and allogeneic dendritic cell therapies designed to activate cytotoxic T cells, offering potential solutions where traditional treatments may fail. With the shift from proof-of-concept studies to clinical-stage developments, notable innovations have emerged, highlighting the efficacy of personalized cell-based immunotherapy. Key drivers include the integration of technology for enhanced antigen discovery, alongside automated manufacturing processes that reduce costs and improve consistency. Additionally, the incorporation of artificial intelligence accelerates clinical development by optimizing patient selection, streamlining operations, and enhancing trial efficiency, ultimately paving the way for broader applications and partnerships in underserved indications.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Dendritic Cell Cancer Vaccine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Dendritic Cell Cancer Vaccine Market Segments Analysis

Global dendritic cell cancer vaccine market is segmented by product type, vaccine type, cancer type, application, end-user and region. Based on product type, the market is segmented into Sipuleucel-T (Provenge), CreaVax and Other. Based on vaccine type, the market is segmented into Autologous Vaccines and Allogeneic Vaccines. Based on cancer type, the market is segmented into Prostate Cancer, Melanoma, Glioblastoma, Breast Cancer and Other Solid Tumors. Based on application, the market is segmented into Therapeutic Cancer Treatment, Adjuvant Therapy and Combination Immunotherapy. Based on end-user, the market is segmented into Hospitals, Cancer Treatment Centers, Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Dendritic Cell Cancer Vaccine Market

One of the key market drivers for the global dendritic cell cancer vaccine market is the increasing demand for personalized cancer therapies. As advancements in immunotherapy continue to reshape cancer treatment paradigms, healthcare providers and patients alike are recognizing the potential of dendritic cell vaccines in eliciting a robust immune response tailored to individual tumor antigens. This shift toward personalized medicine not only enhances treatment efficacy but also minimizes adverse effects associated with traditional therapies. Additionally, rising awareness of the benefits of immunotherapy among patients and healthcare professionals is further propelling the growth of this innovative segment within the oncology market.

Restraints in the Global Dendritic Cell Cancer Vaccine Market

One significant market restraint for the global dendritic cell cancer vaccine market is the high cost and complexity of vaccine production. Dendritic cell vaccines require sophisticated processing and handling, which often involves personalized treatment approaches and significant labor-intensive procedures. This complexity can lead to increased production costs, making it difficult for healthcare providers to offer these therapies at affordable prices. Additionally, the need for specialized facilities and trained personnel further limits the scalability and accessibility of these vaccines, potentially hindering their widespread adoption in the competitive cancer treatment landscape.

Market Trends of the Global Dendritic Cell Cancer Vaccine Market

The Global Dendritic Cell Cancer Vaccine market is witnessing a significant trend towards adaptive combination approaches, underscoring the potential for enhanced antitumor responses through synergistic therapies. As innovators recognize the efficacy of integrating dendritic cell vaccines with other immunotherapeutic strategies, there is an increased focus on developing sequential and concurrent treatment regimens. This collaborative approach aims to maximize T cell priming while utilizing checkpoint inhibitors, cytokine adjuvants, or targeted therapies to combat tumor-induced immune evasion. The market is evolving to favor rational regimen designs, flexible clinical trial methodologies, and robust partnerships within research communities, all geared towards expanding treatment options and validating efficacy through accelerated clinical assessments.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Dendritic Cell Cancer Vaccine Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Sipuleucel-T (Provenge)
• CreaVax
• Other

Global Dendritic Cell Cancer Vaccine Market Size by Vaccine Type & CAGR (2026-2033)

• Market Overview
• Autologous Vaccines
• Allogeneic Vaccines

Global Dendritic Cell Cancer Vaccine Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Prostate Cancer
• Melanoma
• Glioblastoma
• Breast Cancer
• Other Solid Tumors

Global Dendritic Cell Cancer Vaccine Market Size by Application & CAGR (2026-2033)

• Market Overview
• Therapeutic Cancer Treatment
• Adjuvant Therapy
• Combination Immunotherapy

Global Dendritic Cell Cancer Vaccine Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Cancer Treatment Centers
• Research Institutes
• Others

Global Dendritic Cell Cancer Vaccine Market Size & CAGR (2026-2033)

• North America (Product Type, Vaccine Type, Cancer Type, Application, End-User)
  • US
  • Canada
• Europe (Product Type, Vaccine Type, Cancer Type, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Vaccine Type, Cancer Type, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Vaccine Type, Cancer Type, Application, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Vaccine Type, Cancer Type, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Dendreon Pharmaceuticals LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Argos Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunicum AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Northwest Biotherapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DCPrime B.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medigene AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DanDrit Biotech A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kiromic Biopharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AIVITA Biomedical Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ImmunoCellular Therapeutics Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Batavia Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bellicum Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elios Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Activarti
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creagene Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanpower Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shenzhen Geno-Immune Medical Institute
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tella Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OncoTherapy Science Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations